Swissmedic Highlights Post-Market Surveillance Obligations for Legacy Devices
Swissmedic, the Swiss Agency for Therapeutic Products, has released findings from a recent focused action, underscoring the critical importance of robust Post-Market Surveillance (PMS) for all medical devices, including those classified as Legacy Devices (LDs). The review emphasizes that manufacturers must actively monitor the performance and safety of their devices throughout their lifecycle.
The Swissmedic review focused on Periodic Safety Update Reports (PSURs). These reports are crucial for proactively identifying potential risks and ensuring continued device safety and effectiveness.
Key Findings and Implications
The Swissmedic review highlighted several key areas needing improvement among manufacturers. While the specific details of these shortcomings are outlined in the full Swissmedic report, the agency is using the review to remind manufacturers of their obligations.
EU and Swiss Regulations Demand PMS for Legacy Devices
The announcement serves as a timely reminder that both European Union (EU) regulations and Swiss regulationsย requireย manufacturers to meet comprehensive PMS requirements for Legacy Devices. Despite these devices being on the market for some time, manufacturers are not exempt from the responsibility of actively monitoring their safety and performance. This includes:
- Systematic data collection:ย Gathering data from various sources, including user feedback, complaints, and scientific literature.
- Proactive risk assessment:ย Regularly evaluating potential risks associated with the device and taking appropriate corrective actions.
- Transparent reporting:ย Submitting timely and accurate PSURs to regulatory authorities.
Manufacturers who fail to meet these PMS requirements risk facing regulatory action, including device recalls and market withdrawals. Swissmedic emphasizes its commitment to ensuring patient safety and will continue to actively monitor compliance with PMS regulations.
Link to the Swissmedic Report: EN_Schwerpunktaktion_PSUR-final.pdf
Latest news
MHRA Introduces New Device Registration Fee: What Manufacturers Need to Know
The UKโs Medicines and Healthcare products Regulatory Agency (MHRA) has updated its โDORS Fees Guidance 2.1โ, introducing a new annual fee model for device registration.
EUDAMEDโs first four modules become mandatory on 28 May 2026 - what this means for medical device manufacturers
The European Commission (EC) has formally declared that the first four modules of EUDAMED - the European Database on Medical Devices - will become mandatory as of 28 May 2026.
MedNet EC-REP GmbH to Exhibit at WHX 2026 in Dubai
MedNet EC-REP GmbH is excited to announce its participation in WHX 2026, taking place from February 9โ12 in Dubai. As a trusted European Authorized Representative and compliance partner for global medical device manufacturers, we look forward to presenting our comprehensive regulatory services to an international audience.
Implications of the Update to the Borderline & Classification Manual under MDR and IVDR
On 12 September 2025, the European Commission published Version 4 of the Manual on Borderline and Classification under Regulations (EU) 2017/745 and 2017/746, developed by the Borderline and Classification Working Group (BCWG).
Regulatory Affairs Bulletin: Intended Purpose vs Intended Use under MDR & IVDR
European regulations EU 2017/745 (MDR) and EU 2017/746 (IVDR) require precise definitions in technical documentation, and the distinction (or overlap) between intended purpose and intended use remains a topic of operational significance.
-250x250.jpg&w=256&q=75)
MedNet EC-REP GmbH at MEDICA 2025 โ Visit Us in Hall 3, Booth D43
MedNet EC-REP GmbH is pleased to announce that we will once again be exhibiting at MEDICA 2025 in Dรผsseldorf, the worldโs leading trade fair for the medical technology industry.
EU eIFU Regulation Update Draft: What Medical Device Professionals Need to Know
The European Commission has introduced a significant amendment to Implementing Regulation (EU) 2021/2226, impacting how medical device manufacturers provide instructions for use (IFU).
Understanding the Interplay: MDR, IVDR, and the AI Act โ Key Insights from MDCG 2025-6
Recently, the MDCG, in conjunction with the Joint Artificial Intelligence Board (AIB), released the MDCG 2025-6 FAQ document, offering essential clarifications on the interplay between the MDR, the IVDR, and the Artificial Intelligence Act (AIA).